<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="169758">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00886743</url>
  </required_header>
  <id_info>
    <org_study_id>3067K1-2213</org_study_id>
    <secondary_id>B2491001</secondary_id>
    <nct_id>NCT00886743</nct_id>
  </id_info>
  <brief_title>Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia</brief_title>
  <official_title>Study Of The Effects Of Oprelvekin On Cardiac Repolarization In Subjects At Risk Of Severe Thrombocytopenia After Myelosuppressive Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study in which oprelvekin will be administered for the prevention of
      severe low blood platelet cell counts (cells in your blood that keep bleeding and clotting
      stable) in adults with cancer who are taking chemotherapy (anti-cancer drug) that has a side
      effect of blocking your bone marrow from making platelet cells. The purpose of this study is
      to learn more about the effects of the recommended dose of oprelvekin on the heart's
      electrical cycle.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-matched change from baseline in QT interval corrected for heart rate using a population-specific correction formula (QTcN). Based on average across triplicates for a given hourly time point after subcutaneous (SC) administration of oprelvekin.</measure>
    <time_frame>35 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-matched change from baseline in the following QT variables: Fridericia correction (QTcF), Bazett corrections (QTcB)</measure>
    <time_frame>35 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of QTcN, QTcB and QTcF:&gt;=450 msecs, &gt;=480, &gt;=500 msecs, time-matched change from baseline &gt;=30 msecs, time-matched change from baseline &gt;=60 msecs. Based on average across triplicates for a given hourly</measure>
    <time_frame>35 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement.</measure>
    <time_frame>35 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameter Cmax</measure>
    <time_frame>35 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameter tmax</measure>
    <time_frame>35 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-matched changes in vital signs and laboratory data. Based on the value or the average across measures for a given hourly time point if more than 1 measure taken.</measure>
    <time_frame>35 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Severe Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Oprelvekin as subcutaneous injection (50 mg/kg once daily)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Open label treatment with oprelvekin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oprelvekin</intervention_name>
    <description>injection, 50 mg/kg, once daily</description>
    <arm_group_label>Oprelvekin as subcutaneous injection (50 mg/kg once daily)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women must be 18 to 65 years of age, with nonmyeloid malignancies for whom
             oprelvekin is indicated.

          -  At least one documented occasion of adequate hematologic recovery from previous or
             current chemotherapy.

          -  Adequate renal and hepatic excretory function.

        Exclusion Criteria:

          -  A marked baseline prolongation of QT/QTc interval (eg, repeated [two out of three
             readings] demonstration of a QTcF interval &gt;450 msec.

          -  Additional risk factors for torsades de pointes including heart failure (subjects
             that have functional class III or IV congestive heart failure), hypokalemia,
             hypomagnesemia, or hypocalcemia.

          -  A pace maker or defibrillator.

          -  A history of LQTS, syncope, seizure, or the unexplained cardiac-related death of a
             family member at less than 30 years of age.

          -  Requirement of concomitant prescription or non-prescription medications or dietary
             supplements that have a risk of causing torsades de pointes or prolonged QT/QTc
             interval.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sarcoma Oncology Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montgomery Cancer Center</name>
      <address>
        <city>Mount Sterling</city>
        <state>Kentucky</state>
        <zip>40353</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Dover</city>
        <state>Ohio</state>
        <zip>44622</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Signal Point Hematology / Oncology Inc</name>
      <address>
        <city>Middletown</city>
        <state>Ohio</state>
        <zip>45042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flavio Castaneda M.D.</name>
      <address>
        <city>Laredo</city>
        <state>Texas</state>
        <zip>78041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Research Alliance LLC.</name>
      <address>
        <city>Laredo</city>
        <state>Texas</state>
        <zip>78041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3067K1-2213&amp;StudyName=Study%20Evaluating%20The%20Effects%20Of%20Oprelvekin%20On%20Cardiac%20Repolarization%20In%20Subjects%20With%20Chemotherapy%20Induced%20Thrombocytopenia</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 5, 2016</lastchanged_date>
  <firstreceived_date>April 22, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oprelvekin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
